Kathleen M Darcy1, Michael J Birrer. 1. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. darcy@gogstats.org
Abstract
OBJECTIVES: To review the translational research (TR) performed in the Gynecologic Oncology Group (GOG) to evaluate ovarian cancer markers, profiles and novel therapies. METHODS: Prospective trials with stand alone or embedded TR objectives involving patient and specimen accrual as well as retrospective studies using banked specimens and resources were and continue to be performed in the GOG. Appropriate statistical methods are employed to evaluate associations with clinical characteristics and outcomes including tumor response, adverse events, progression free survival and overall survival. RESULTS: Highlights are presented for some of the collaborative and multidisciplinary TR conducted with the GOG to evaluate markers, pathway and novel therapeutics in epithelial ovarian, primary peritoneal and/or fallopian tube cancer. For example, in GOG 111, high immunohistochemical (IHC) expression of cyclin E was associated with a shorter median survival (29 versus 35 months) and an increased risk of death (hazard ratio [HR]=1.4, 95% confidence interval [CI]=1.0-2.1, p=0.05). In GOG 114/132, non-detectable immunoblot expression of maspin was associated with debulking status (p=0.034) and an increased risk of disease progression (HR=1.89, 95% CI=1.04-3.45, p=0.038) and death (HR=1.99, 95% CI=1.07-3.69, p=0.030) while high CD105-microvessel density (MVD), but not CD31-MVD in tumor was associated with increased risk of disease progression (HR=1.873, 95% CI=1.102-3.184, p=0.020) but not death. In GOG 172, low IHC expression of BRCA1 was associated with advanced stage (p<0.001), serous histology (p<0.001) and a reduced risk of disease progression (HR=0.64, 95% CI=0.42-0.96) and death (HR=0.51, 95% CI=0.32-0.83) while the CA/AA versus CC genotypes in C8092A in ERCC1 were associated with an increased risk of disease progression (HR=1.44, 95% CI=1.06-1.94, p=0.018) and death (HR=1.50, 95% CI=1.07-2.09, p=0.018). CONCLUSIONS: The GOG has an extensive TR program that provides clues regarding the molecular and biochemical mechanisms of disease, treatments and outcomes in women with or at risk for a gynecologic malignancy. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To review the translational research (TR) performed in the Gynecologic Oncology Group (GOG) to evaluate ovarian cancer markers, profiles and novel therapies. METHODS: Prospective trials with stand alone or embedded TR objectives involving patient and specimen accrual as well as retrospective studies using banked specimens and resources were and continue to be performed in the GOG. Appropriate statistical methods are employed to evaluate associations with clinical characteristics and outcomes including tumor response, adverse events, progression free survival and overall survival. RESULTS: Highlights are presented for some of the collaborative and multidisciplinary TR conducted with the GOG to evaluate markers, pathway and novel therapeutics in epithelial ovarian, primary peritoneal and/or fallopian tube cancer. For example, in GOG 111, high immunohistochemical (IHC) expression of cyclin E was associated with a shorter median survival (29 versus 35 months) and an increased risk of death (hazard ratio [HR]=1.4, 95% confidence interval [CI]=1.0-2.1, p=0.05). In GOG 114/132, non-detectable immunoblot expression of maspin was associated with debulking status (p=0.034) and an increased risk of disease progression (HR=1.89, 95% CI=1.04-3.45, p=0.038) and death (HR=1.99, 95% CI=1.07-3.69, p=0.030) while high CD105-microvessel density (MVD), but not CD31-MVD in tumor was associated with increased risk of disease progression (HR=1.873, 95% CI=1.102-3.184, p=0.020) but not death. In GOG 172, low IHC expression of BRCA1 was associated with advanced stage (p<0.001), serous histology (p<0.001) and a reduced risk of disease progression (HR=0.64, 95% CI=0.42-0.96) and death (HR=0.51, 95% CI=0.32-0.83) while the CA/AA versus CC genotypes in C8092A in ERCC1 were associated with an increased risk of disease progression (HR=1.44, 95% CI=1.06-1.94, p=0.018) and death (HR=1.50, 95% CI=1.07-2.09, p=0.018). CONCLUSIONS: The GOG has an extensive TR program that provides clues regarding the molecular and biochemical mechanisms of disease, treatments and outcomes in women with or at risk for a gynecologic malignancy. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: K M Darcy; D Zangani; A L Wohlhueter; R Y Huang; M M Vaughan; J A Russell; M M Ip Journal: J Histochem Cytochem Date: 2000-01 Impact factor: 2.479
Authors: F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Elizabeth L Jewell; Kathleen M Darcy; Alan Hutson; Paula S Lee; Laura J Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord Journal: Gynecol Oncol Date: 2009-09-19 Impact factor: 5.482
Authors: Carol Aghajanian; John A Blessing; Kathleen M Darcy; Gary Reid; Koen DeGeest; Stephen C Rubin; Robert S Mannel; Jacob Rotmensch; Russell J Schilder; William Riordan Journal: Gynecol Oncol Date: 2009-08-26 Impact factor: 5.482
Authors: Antonis C Antoniou; Olga M Sinilnikova; Lesley McGuffog; Sue Healey; Heli Nevanlinna; Tuomas Heikkinen; Jacques Simard; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Susan L Neuhausen; Yuan C Ding; Fergus J Couch; Xianshu Wang; Zachary Fredericksen; Paolo Peterlongo; Bernard Peissel; Bernardo Bonanni; Alessandra Viel; Loris Bernard; Paolo Radice; Csilla I Szabo; Lenka Foretova; Michal Zikan; Kathleen Claes; Mark H Greene; Phuong L Mai; Gad Rennert; Flavio Lejbkowicz; Irene L Andrulis; Hilmi Ozcelik; Gord Glendon; Anne-Marie Gerdes; Mads Thomassen; Lone Sunde; Maria A Caligo; Yael Laitman; Tair Kontorovich; Shimrit Cohen; Bella Kaufman; Efrat Dagan; Ruth Gershoni Baruch; Eitan Friedman; Katja Harbst; Gisela Barbany-Bustinza; Johanna Rantala; Hans Ehrencrona; Per Karlsson; Susan M Domchek; Katherine L Nathanson; Ana Osorio; Ignacio Blanco; Adriana Lasa; Javier Benítez; Ute Hamann; Frans B L Hogervorst; Matti A Rookus; J Margriet Collee; Peter Devilee; Marjolijn J Ligtenberg; Rob B van der Luijt; Cora M Aalfs; Quinten Waisfisz; Juul Wijnen; Cornelis E P van Roozendaal; Susan Peock; Margaret Cook; Debra Frost; Clare Oliver; Radka Platte; D Gareth Evans; Fiona Lalloo; Rosalind Eeles; Louise Izatt; Rosemarie Davidson; Carol Chu; Diana Eccles; Trevor Cole; Shirley Hodgson; Andrew K Godwin; Dominique Stoppa-Lyonnet; Bruno Buecher; Mélanie Léoné; Brigitte Bressac-de Paillerets; Audrey Remenieras; Olivier Caron; Gilbert M Lenoir; Nicolas Sevenet; Michel Longy; Sandra Fert Ferrer; Fabienne Prieur; David Goldgar; Alexander Miron; Esther M John; Saundra S Buys; Mary B Daly; John L Hopper; Mary Beth Terry; Yosuf Yassin; Christian Singer; Daphne Gschwantler-Kaulich; Christine Staudigl; Thomas v O Hansen; Rosa Bjork Barkardottir; Tomas Kirchhoff; Prodipto Pal; Kristi Kosarin; Kenneth Offit; Marion Piedmonte; Gustavo C Rodriguez; Katie Wakeley; John F Boggess; Jack Basil; Peter E Schwartz; Stephanie V Blank; Amanda E Toland; Marco Montagna; Cinzia Casella; Evgeny N Imyanitov; Anna Allavena; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Nina Ditsch; Norbert Arnold; Dieter Niederacher; Helmut Deissler; Britta Fiebig; Christian Suttner; Ines Schönbuchner; Dorothea Gadzicki; Trinidad Caldes; Miguel de la Hoya; Karen A Pooley; Douglas F Easton; Georgia Chenevix-Trench Journal: Hum Mol Genet Date: 2009-08-05 Impact factor: 6.150
Authors: Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer Journal: Gynecol Oncol Date: 2009-06-12 Impact factor: 5.482
Authors: Julie A Deloia; Nikhil R Bhagwat; Kathleen M Darcy; Mary Strange; Chunquio Tian; Kevin Nuttall; Thomas C Krivak; Laura J Niedernhofer Journal: Gynecol Oncol Date: 2012-05-16 Impact factor: 5.482
Authors: Ingiridur Skirnisdottir; Markus Mayrhofer; Maria Rydåker; Helena Akerud; Anders Isaksson Journal: BMC Cancer Date: 2012-09-12 Impact factor: 4.430